There has been an increase in the number of patients with refractory hematological malignancies being referred to transplant centers, although previously, treatment was limited for refractory conditions. In this talk, Mohamad Mohty, MD, PhD, from Saint-Antoine Hospital, Paris, France, alludes to the optimism regarding allogeneic therapy for patients with refractory hematological malignancies. Talking from the 2018 European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting in Lisbon, Portugal, Prof. Mohty discusses the potential candidates for allogeneic transplantation.
Allogeneic therapy for the treatment of refractory hematological malignancies
